Eupraxia Pharmaceuticals Inc.
TSX:EPRX.TOBiotechnology
+$0.22 today
- Market cap
- $595.76M
- Beta
- 1.48
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.74
Volume 0.16M
Average 0.05M
EPRX.TO EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Eupraxia Pharmaceuticals Inc.TSX: EPRX.TO
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$15.61M, compared with -$4.72M a year earlier. Trailing-twelve-month EBITDA was -$44.63M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -65.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$15.61M+4.5% QoQ
- Last fiscal yearDec 2025
- -$38.86M-65.9% YoY
- LTMMar 2026
- -$44.63M-141.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -230.8% | +100.0% | +330.8 pp |
| 1 year | -65.9% | +100.0% | +165.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
Mixed currencies · from the income statement
- Latest · FY2025
- (38.86M) USD
- Year-over-year change
- -65.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (38.86M) | -65.9% |
| FY2024 | 2024-12-31 | (23.43M) | +16.8% |
| FY2023 | 2023-12-31 | (28.16M) | — |
| FY2022 | 2022-12-31 | (22.14M) | -0.8% |
| FY2021 | 2021-12-31 | (21.96M) | — |
EBITDA vs competitors
How EPRX.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -141.2% is the 7th highest of 8, against a peer median of +48.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $75.52M USD | -3.6% | +5.1% | 24.7% | |
| LTM Mar 2026 | $60.46M USD | +510.4% | — | 23.1% | |
| LTM Apr 2026 | -CA$3.08M CAD | +67.7% | — | — | |
| LTM Mar 2026 | -$5.36M USD | +48.2% | — | 10.5% | |
PRN.TOProfound Medical Corp. | LTM Mar 2026 | -$36.45M USD | -1.4% | — | 194.3% |
| LTM Mar 2026 | -CA$40.84M CAD | -681.4% | — | 14.9% | |
| LTM Mar 2026 | -$44.63M USD | -141.2% | — | — | |
| LTM Mar 2026 | -CA$63.48M CAD | +86.8% | — | 20.4% | |
| Peer median (excluding EPRX.TO) | — | +48.2% | +5.1% | 21.8% | |
Competitors are the stored peer set for EPRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · USD | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 111.53K | 193.27K | 158.05K | 163.47K | 241.88K |
| Gross Profit | (111.53K) | (193.27K) | (158.05K) | (163.47K) | (241.88K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 10.17M | 17.58M | 21M | 15.17M | 21.51M |
| Selling, General & Admin | 8.2M | 5.81M | 7.37M | 10.92M | 17.1M |
| Operating Expenses | 18.38M | 23.38M | 28.37M | 25.54M | 38.86M |
| Depreciation & Amortization | 111.53K | 193.27K | 158.05K | 163.47K | 241.88K |
| EBITDA | (21.96M) | (22.14M) | (28.16M) | (23.43M) | (38.86M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (18.47M) | (23.58M) | (27.78M) | (25.71M) | (39.11M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 65.73K | 569.32K | 876.96K | 1.1M | 1.44M |
| Interest Expense | 1.3M | 1.59M | 1.19M | 913.1K | 0 |
| Other Income / Expenses | (4.9M) | (341.09K) | (1.08M) | 1.2M | (155.19K) |
| Income Before Tax | (23.37M) | (23.92M) | (28.93M) | (24.51M) | (39.26M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | (67.51K) | 1.72K | 19.42K |
| Net Income | (22.99M) | (23.26M) | (28.15M) | (24.28M) | (39.25M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.61) | (1.21) | (1.19) | (0.72) | (1.05) |
| EPS (Diluted) | (1.61) | (1.21) | (1.19) | (0.72) | (1.05) |
| Weighted Avg Shares | 14.24M | 19.29M | 24.15M | 33.93M | 39.96M |
| Weighted Avg Shares (Diluted) | 14.24M | 19.29M | 24.15M | 33.93M | 39.96M |
Eupraxia Pharmaceuticals Inc.
TSX:EPRX.TO
Intrinsic Alpha fair value
Locked
Current Price
$8.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.